The Technical Analyst
Stealth BioTherapeutics [MITO]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Stealth BioTherapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.320
/ 15 nov 2022 @ 16:00
| RATING 2022-11-16 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.346 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.346 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.314 - 0.326 ( +/- 1.88%) |
| ATR Model: 14 days |
Forecast:
01:40 - $0.341
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.320 (0.00% ) |
| Volume | 1.300 mill |
| Avg. Vol. | 0.202 mill |
| % of Avg. Vol | 643.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MITO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MITO
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
Latest Press Releases
2024-04-08 08:00:00 - Press Release
Stealth Biotherapeutics Announces Fda Acceptance Of New Drug Application For Elamipretide For The Treatment Of Barth Syndrome
Barth syndrome is an ultra-rare, progressive, life-shortening, cardioskeletal disease that affects approximately 150 individuals in the united states if approved, elamipretide would become the first approved therapy for barth syndrome needham, mass. , april 8, 2024 /prnewswire/ -- stealth biotherapeutics , a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the u.s. food and drug administration ("fda") has accepted for filing its new drug application ("nda") for elamipretide for the treatment of barth syndrome.
2023-12-04 07:30:00 - Press Release
Stealth Biotherapeutics To Present At The Baird 2023 Biotech Discovery Series
Needham, mass. , dec. 4, 2023 /prnewswire/ -- stealth biotherapeutics inc. (the "company" or "stealth"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that reenie mccarthy, chief executive officer, and brian blakey, chief business officer, will participate in a fireside chat at the baird biotech discovery series on tuesday, december 5, 2023, at 11:30 am et.
2022-03-09 17:00:00 - Press Release
Stealth Biotherapeutics To Present At Upcoming March Investor Conferences
Boston , march 9, 2022 /prnewswire/ -- stealth biotherapeutics corp (nasdaq:mito), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that reenie mccarthy, ceo, will present at three upcoming investor conferences in march: oppenheimer 32nd annual healthcare conference. pre-recorded presentation available for on-demand viewing starting on tuesday, march 15 at 4:40 p.m.
2022-02-22 07:30:00 - Press Release
Stealth Biotherapeutics To Present At Mitochondria-targeted Drug Development Summit
Boston, feb. 22, 2022 /prnewswire/ -- stealth biotherapeutics corp (nasdaq:mito), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that reenie mccarthy, ceo, will present at the virtual mitochondria-targeted drug development summit on thursday, february 24, 2022 at 9:00 a.m. et. reenie mccarthy's presentation is titled, "mitochondria as a target for ophthalmic disease," which will focus on mitochondrial dysfunction as a key pathology in ophthalmic conditions such as dry age-related macular degeneration (amd), glaucoma, diabetic retinopathy and fuch's corneal endothelial dystrophy.
2022-01-04 07:30:00 - Press Release
Stealth Biotherapeutics To Present At 2022 H.c. Wainwright Bioconnect Virtual Conference
Boston, jan. 4, 2022 /prnewswire/ -- stealth biotherapeutics corp (nasdaq: mito), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that reenie mccarthy, ceo, will present at the h.c. wainwright bioconnect virtual conference taking place from january 10-13, 2022.
Latest News
2022-06-08 15:16:13 - PennyStocks
Good Penny Stocks to Buy Today? 3 to Watch Right Now
Here are three penny stocks to watch right now The post Good Penny Stocks to Buy Today? 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-06-08 09:47:05 - Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
Stealth BioTherapeutics Corp (NASDAQ: MITO) presented new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology. TDP-43 pathology plays a significant role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
2022-05-10 08:00:00 - PennyStocks
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-02 09:25:07 - Benzinga
Stealth Bio Posts Disappointing Elamipretide Data From Mid-Stage Geographic Atrophy Study
Stealth BioTherapeutics Corp (NASDAQ: MITO) has announced topline data from its Phase 2 ReCLAIM-2 trial evaluating elamipretide in geographic atrophy (GA) secondary to dry age-related macular degeneration. Although the trial did not meet its primary endpoints, a key secondary.
2022-03-09 17:00:00 - PRNewsWire
Stealth BioTherapeutics to Present at Upcoming March Investor Conferences
BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at three upcoming investor conferences in March: Oppenheimer 32nd Annual Healthcare Conference. Pre-recorded presentation available for on-demand viewing starting on Tuesday, March 15 at 4:40 p.m.
2022-02-22 07:30:00 - PRNewsWire
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m. ET. Reenie McCarthy's presentation is titled, "Mitochondria as a Target for Ophthalmic Disease," which will focus on mitochondrial dysfunction as a key pathology in ophthalmic conditions such as dry age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and Fuch's corneal endothelial dystrophy.
2022-01-04 07:30:00 - PRNewsWire
Stealth BioTherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
BOSTON, Jan. 4, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022.
2021-11-11 13:25:32 - Seeking Alpha
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q3 2021 Results - Earnings Call Transcript
2021-10-20 09:14:28 - Benzinga
Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate
Stealth BioTherapeutics Corp (NASDAQ: MITO) has received a Refusal to File letter from the FDA regarding its marketing application for elamipretide, a mitochondria-targeted therapy for Barth syndrome. Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities often leading to heart failure and reduced life expectancy, recurrent infections, muscle weakness, and delayed growth.
2021-10-07 17:00:00 - PRNewsWire
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
BOSTON, Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of amyotrophic lateral sclerosis (ALS). The data were presented at the virtual 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting held October 6-7, 2021.